Background and Aim
Hepatitis B virusârelated acuteâonâchronic liver failure (HBVâACLF) is characterized by acute deterioration of chronic liver disease with excessive inflammation. Nâmyc and STAT interactor (NMI), an inflammationâmediated protein, involves in various inflammatoryârelated diseases, but the role of NMI in development and prognosis in HBVâACLF remains to be elucidated.
Methods
Serum NMI from healthy controls (HCs, n = 20), chronic hepatitis B (CHB, n = 50) patients, and HBVâACLF patients (n = 50) was determined using ELISA. NMI from peripheral blood mononuclear cells and liver was confirmed using quantitative realâtime polymerase chain reaction, Western blot, and immunofluorescence.
Results
Serum NMI was increased 1.9âfold or 2.2âfold from HBVâACLF patients compared with that from HCs (P < 0.01) or CHB patients (P < 0.01). Consistently, NMI from peripheral blood mononuclear cells was upregulated significantly from HBVâACLF patients compared with that from HCs and CHB patients at mRNA and protein levels. Hepatic NMI from HBVâACLF patients was 2.8âfold higher than that from HCs. Serum NMI was correlated with Model for Endâstage Liver Disease, Chronic Liver Failure Consortium ACLF score, and ACLF grades. In contrast, serum NMI was significantly decreased in HBVâACLF ameliorated patients during followâup, whereas serum NMI was sustained at high levels in nonâameliorated patients. Elevated serum NMI (â„ 198.5 pg/mL) was correlated with poor survival rate of HBVâACLF patients. Using receiver operating characteristics curves, it was suggested that serum NMI was a potential biomarker in predicting 3âmonth mortality of HBVâACLF patients.
Conclusions
Our study highlights the potential role of NMI in assessing the development and prognosis of HBVâACLF.